In the highly regulated world of pharmaceutical manufacturing, the quality and purity of raw materials and intermediates are non-negotiable. For compounds like Methyl 5-chloro-3-(chlorosulfonyl)-2-thiophenecarboxylate, identified by CAS number 126910-68-7, adherence to strict specifications is paramount. This intermediate is a critical component in the synthesis of Lornoxicam, and any deviation in its quality can have significant repercussions on the final drug product's efficacy, safety, and regulatory compliance.

When sourcing this essential pharmaceutical intermediate, buyers must pay close attention to several key specifications. The appearance, typically a yellow powder, serves as an initial visual check. More importantly, the assay value, commonly determined by High-Performance Liquid Chromatography (HPLC), indicates the purity of the compound. A minimum assay of ≥95.0% is generally expected, but higher purities may be required for sensitive applications. This high purity is vital because impurities, even in trace amounts, can interfere with downstream reactions, lead to unwanted byproducts, or pose toxicological risks in the final API.

Manufacturers that provide Methyl 5-chloro-3-(chlorosulfonyl)-2-thiophenecarboxylate must demonstrate robust quality control measures. This includes well-documented testing procedures, validated analytical methods, and comprehensive Certificates of Analysis (CoA) for each batch. Buyers seeking to purchase CAS 126910-68-7 should look for suppliers who are transparent about their quality systems and are willing to provide detailed product information. Understanding the molecular formula (C6H4Cl2O4S2) and molecular weight (275.13) also helps in verifying the product's identity.

The stability and appropriate storage conditions are also crucial considerations. Storing Methyl 5-chloro-3-(chlorosulfonyl)-2-thiophenecarboxylate in a cool, ventilated place, as recommended, helps maintain its integrity over time. By prioritizing suppliers who can consistently deliver material that meets or exceeds these critical specifications, pharmaceutical companies can ensure the reliability and safety of their Lornoxicam production and other related drug syntheses. The investment in high-quality intermediates translates directly into confidence in the final pharmaceutical product.